Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - meglumine; sodium hydroxide ; sodium amidotrizoate - solution for infusion - 30 percent weight/volume - diatrizoic acid

Malta - English - Medicines Authority

bayer hellas s.a 6-8 agisilaou street 151 23 marousi attiki, , greece - meglumine amidotrizoate, sodium amidotrizoate - gastroenteral solution - sodium amidotrizoate 10 g/100ml meglumine amidotrizoate 66 g/100ml - contrast media

Malta - English - Medicines Authority

bayer plc - meglumine amidotrizoate; sodium amidotrizoate - gastroenteral solution - meglumine amidotrizoate 660 mg/ml; sodium amidotrizoate 100 mg/ml - contrast media

United States - English - NLM (National Library of Medicine)

amersham health inc. - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoate - unii:), diatrizoate sodium (unii: v5403h8vg7) (diatrizoate - unii:) - injection, solution - 660 mg in 1 ml - hypaque-76 is indicated for excretory urography, aortography, angiocardiography (ventriculography, pulmonary angiography, selective coronary arteriography), peripheral angiography (peripheral arteriography and peripheral venography), intravenous digital arteriography, contrast enhancement of computed tomographic head imaging, contrast enhancement of computed tomographic body imaging, selective renal arteriography, selective visceral arteriography, central venography, and renal venography. in addition to the following generalcontraindications, warnings, precautions, and adverse reactions, there are additional listings in these categories under the particular procedures. hypaque-76 has no absolute contraindications in its recommended uses (see general warnings and precautions). do not use hypaque-76 for myelography or for examination of dorsal cysts or sinuses which might communicate with the subarachnoid space. even a small amount in the subarachnoid space may produce convulsions and result in fatality. (see

United States - English - NLM (National Library of Medicine)

amersham health inc. - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk) - injection, solution - 30 g in 100 ml - hypaque-cysto is indicated for retrograde cystourethrography in adult and pediatric patients. hypaque-cysto has no absolute contraindication in its recommended use.

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - sodium amidotrizoate; amidotrizoate meglumine; amidotrizoic acid; meglumine - oral/rectal solution - 660 and 100 milligram(s)/millilitre - watersoluble, hepatotropic x-ray contrast media; sodium iopodate

Canada - English - Health Canada

bracco imaging canada - diatrizoate meglumine; diatrizoate sodium - solution - 66%; 10% - diatrizoate meglumine 66%; diatrizoate sodium 10% - roentgenography

Canada - English - Health Canada

ge healthcare canada inc - diatrizoate sodium - powder - 997.4mg - diatrizoate sodium 997.4mg - roentgenography

Canada - English - Health Canada

bracco imaging canada - diatrizoate meglumine - liquid - 600mg - diatrizoate meglumine 600mg - roentgenography

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - meglumine amidotrizoate; sodium amidotrizoate - solution - 0.66 g/ml - meglumine amidotrizoate 0.66 g/ml; sodium amidotrizoate 0.1 g/ml